增强剂量免疫化疗联合一线自体外周血造血干细胞移植治疗年轻高危侵袭性B细胞淋巴瘤的疗效及预后因素分析
回顾性分析2011年1月至2018年12月中国医学科学院血液病医院63例初治年轻高危侵袭性B细胞淋巴瘤患者,接受增强剂量免疫化疗联合ASCT一线治疗,中位随访50个月,3年PFS率(83.9±4.7)%、OS率(90.4±3.7)%,骨髓受累为独立不良预后因素。
要点
- 63例年轻高危侵袭性B细胞淋巴瘤患者一线接受增强剂量免疫化疗联合ASCT,3年PFS率(83.9±4.7)%、OS率(90.4±3.7)%。
- 单因素分析示年龄调整的国际预后指数评分≥2分是影响OS的不良因素(P=0.039)。
- 多因素分析示骨髓受累是OS(P=0.016)和PFS(P=0.001)的唯一独立不良预后因素。
核心结论
- 一线应用增强剂量免疫化疗联合ASCT治疗年轻高危侵袭性B细胞淋巴瘤可获得良好的长期疗效,骨髓受累为不良预后因素。
研究设计与样本
- 回顾性研究,分析2011年1月至2018年12月中国医学科学院血液病医院63例初治年轻高危侵袭性B细胞淋巴瘤患者的临床和生存资料。
主要发现
- 63例患者中位年龄40(14~63)岁,诱导方案为R-DA-EP(D)OCH 52例、R-HyperCVAD/R-MA 11例。
- 16例(25.4%)患者中期疗效评估为部分缓解,其中10例移植后获得完全缓解。
- 中位随访50(8~112)个月,3年PFS率为(83.9±4.7)%、OS率为(90.4±3.7)%。
- 单因素分析显示年龄调整的国际预后指数评分≥2分是影响OS的不良因素(P=0.039),骨髓受累是影响OS(P<0.001)和PFS(P=0.001)的不良因素。
- 多因素分析显示骨髓受累是OS(P=0.016)和PFS(P=0.001)的唯一独立不良预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to determine the efficacy of dose-enhanced immunochemotherapy followed by autologous peripheral blood stem cell transplantation (ASCT) in young patients with newly diagnosed high-risk aggressive B-cell lymphoma. Methods: A retrospective study was conducted to examine the clinical and survival data of young patients with high-risk aggressive B-cell lymphoma who received dose-enhanced immunochemotherapy and ASCT as first-line treatment between January 2011 and December 2018 in Blood Diseases Hospital. Results: A total of 63 patients were included in the study. The median age range was 40 (14-63) years old. In terms of the induction therapy regimen, 52 cases received R-DA-EP (D) OCH, and the remaining 11 received R-HyperCVAD/R-MA. Sixteen (25.4% ) patients achieved partial response in the mid-term efficacy assessment, and ten of them were evaluated as complete response after transplantation. The median follow-up was 50 (8-112) months, and the 3-year progression-free survival (PFS) rate and overall survival (OS) rate were (83.9±4.7) % and (90.4±3.7) % , respectively. Univariate analysis demonstrated that age-adjusted international prognostic index ≥2 scores was a negative prognostic factor for OS (P=0.039) , and bone marrow involvement (BMI) was an adverse prognostic factor for OS (P<0.001) and PFS (P=0.001) . However, multivariate analysis confirmed that BMI was the only independent negative predictor of OS (P=0.016) and PFS (P=0.001) . Conclusions: The use of dose-enhanced immunochemotherapy in combination with ASCT as first-line therapy in the treatment of young, high-risk aggressive B-cell lymphoma results in good long-term outcomes, and BMI remains an adverse prognostic factor. 目的: 探讨增强剂量免疫化疗联合自体外周血造血干细胞移植(ASCT)治疗初治、年轻、高危侵袭性B细胞淋巴瘤患者的疗效及预后因素。 方法: 回顾性分析2011年1月至2018年12月在中国医学科学院血液病医院应用增强剂量免疫化疗联合ASCT治疗的63例初治、年轻、高危侵袭性B细胞淋巴瘤患者的临床和生存资料。 结果: 63例患者的中位年龄为40(14~63)岁。诱导治疗方案包括R-DA-EP(D)OCH(52例)和R-HyperCVAD/R-MA(11例)。16例(25.4%)患者中期疗效评估为部分缓解,其中10例移植后获得完全缓解。中位随访50(8~112)个月,3年无进展生存(PFS)率和总生存(OS)率分别为(83.9±4.7)%和(90.4±3.7)%。单因素分析显示年龄调整的国际预后指数评分≥2分是影响OS的预后不良因素(P=0.039),骨髓受累(BMI)是影响OS(P<0.001)和PFS(P=0.001)的预后不良因素。多因素分析显示BMI是OS(P=0.016)和PFS(P=0.001)的唯一独立预后不良因素。 结论: 一线应用增强剂量免疫化疗联合ASCT治疗年轻、高危侵袭性B细胞淋巴瘤可获得良好的长期疗效,BMI为不良预后因素。.
引用
- Wang Y, Liu W, Huang WY, et al. [Dose-enhanced immunochemotherapy followed by first-line autologous peripheral blood stem cell transplantation for young patients with high-risk aggressive B-cell lymphoma: an efficacy and prognostic factor analysis]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35405779. doi:10.3760/cma.j.issn.0253-2727.2022.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。